Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles
ACS Materials Au · 08.11.2023 · 3 (6) · 584-599
DOI: 10.1021/acsmaterialsau.3c00035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Materials Au, online erschienen am 27.07.2023. Verfasst von Jinhui Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscien…. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, P.R. China.
- University of Chinese Academy of Sciences, Beijing 100049, P.R. China.
ORCID-Profile: Chunying Chen, Ying Liu
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Lin, J., Wang, X., Ni, D., Chen, Y., Chen, C., & Liu, Y. (2023). Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles. ACS Materials Au, 3(6), 584-599. https://doi.org/10.1021/acsmaterialsau.3c00035
Vancouver
Lin J, Wang X, Ni D, Chen Y, Chen C, Liu Y. Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles. ACS Materials Au. 2023;3(6):584-599. doi:10.1021/acsmaterialsau.3c00035
BibTeX
@article{Lin2023,
author = {Lin, Jinhui and Wang, Xinlian and Ni, Dongqi and Chen, Yandong and Chen, Chunying and Liu, Ying},
title = {Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles},
journal = {ACS Materials Au},
year = {2023},
volume = {3},
number = {6},
pages = {584--599},
doi = {10.1021/acsmaterialsau.3c00035}
}
EUVIMED